DeFord John A 4
4 · NUVASIVE INC · Filed Sep 5, 2023
Insider Transaction Report
Form 4
NUVASIVE INCNUVA
DeFord John A
Director
Transactions
- Disposition to Issuer
Restricted Stock Unit
2023-09-01−563→ 0 total→ Common Stock (563 underlying) - Disposition to Issuer
Restricted Stock Unit
2023-09-01−2,577→ 0 total→ Common Stock (2,577 underlying) - Disposition to Issuer
Restricted Stock Unit
2023-09-01−2,702→ 0 total→ Common Stock (2,702 underlying) - Disposition to Issuer
Restricted Stock Unit
2023-09-01−3,230→ 0 total→ Common Stock (3,230 underlying) - Disposition to Issuer
Restricted Stock Unit
2023-09-01−3,095→ 0 total→ Common Stock (3,095 underlying) - Disposition to Issuer
Restricted Stock
2023-09-01−3,788→ 0 total→ Common Stock (3,788 underlying) - Disposition to Issuer
Restricted Stock Unit
2023-09-01−4,816→ 0 total→ Common Stock (4,816 underlying)
Footnotes (2)
- [F1]Represented a contingent right to receive one share of the Issuer's common stock upon vesting.
- [F2]Pursuant to the Agreement and Plan of Merger, dated as of February 8, 2023 (the "Merger Agreement"), by and among the Issuer, Globus Medical, Inc. ("Globus") and Zebra Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Globus. At the effective time of the merger, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive 0.75 shares of Class A common stock of Globus, par value $0.001 per share, and cash in lieu of fractional shares, in respect of each share of Issuer common stock underlying such award.